 Predictive biomarkers for Sakatuzumab Govetican efficacy in Trop2-expressing triple-negative breast cancer. In a research paper published by Alkotarget in 2020, researchers analyzed the antibody drug conjugate Sakatuzumab Govetican or SB. The team investigated whether there are biomarkers that can predict sensitivity to SB in triple-negative breast cancers. Read this study in more peer-reviewed oncology-focused research published by Alkotarget.